SLXN ▼ -15.6% - Silexion Therapeutics Corp
$SLXN - Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
30-SEP-2026 08:00 AM ET
Share this post
More filings for $SLXN
SLXN ▲ +28.0% - Silexion Therapeutics CorpSep 29, 2026SLXN - Silexion Therapeutics Corp - SEC Filing Update (28-SEP-2026) | ThinkSabio - Stocks SimplifiedSep 28, 2026SLXN ▲ +2.9% - Silexion Therapeutics CorpSep 9, 2026SLXN - Silexion Therapeutics Corp - SEC Filing Update (19-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 20, 2026SLXN - Silexion Therapeutics Corp - SEC Filing Update (18-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 18, 2026$SLXN SEC Filing Update (23-JUN-2026) | ThinkSabio - Stocks SimplifiedJun 23, 2026
View full $SLXN filing history →💬 Comments
Loading comments…
Leave a comment